EMA CHMP Chair Re-elected
Tomas Salmonson is re-elected as Chair of the Committee for Medicinal Products for Human Use.
The European Medicines Agency (EMA) announced on Sept. 21, 2015 that Dr. Tomas Salmonson has been re-elected as Chair of the Committee for Medicinal Products for Human Use (CHMP). Salmonson is senior scientific advisor at the Swedish Medical Products Agency, has been a member of CHMP for more than 15 years, and has served as CHMP chair for the past three years.
According to an EMA press release, in his second term, Salmonson plans on deepening stakeholder collaboration, facilitating the development of and access to innovative medicines, and improving benefit-risk methodologies.
In response to his re-election, Salmonson stated, “It is a great honor for me to receive the backing of my peers for another term. I have a deep respect and appreciation for the work of the dedicated and professional members of the Committee. CHMP is a forum for open discussion. Debate between members with different backgrounds and views is an essential element in delivering robust scientific opinions. I look forward to working even harder to maintain and strengthen this fruitful working environment in order to fulfill our public health mandate.”
Source: European Medicines Agency
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
